Grace Kong

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 5

Top Topics

Neuroendocrine Tumors

Patient Reported

Top Venues

European journal of nuclear medicine and molecular imaging

Current oncology reports

JMIR research protocols

This page only lists publications with an associated author ORCID identifier.

Publications

Grace Kong, Emma Boehm, Owen Prall, William K Murray, Richard W Tothill, Michael Michael
Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN). Current oncology reports (2023)
Lamiaa Zidan, Amir Iravani, Grace Kong, Tim Akhurst, Michael Michael, Rodney John Hicks
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT. European journal of nuclear medicine and molecular imaging 48 (1) (2020)
Lisa Guccione, Karla Gough, Allison Drosdowsky, Krista Fisher, Timothy Jay Price, Nick Pavlakis, Mustafa Khasraw, David K Wyld, David Ransom, Grace Kong, Megan Rogers, Simone Leyden, John Leyden, Michael Michael, Penelope Schofield
Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR research protocols 8 (12) (2019)
Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, Tim Akhurst, Amichay Meirovitz, Ofra Maimon, Yodphat Krausz, Jeremy Godefroy, Michael Michael, David J Gross, Rodney J Hicks
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). European journal of nuclear medicine and molecular imaging 46 (3) (2018)
Grace Kong, Jason Callahan, Michael S Hofman, David A Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J Hicks
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European journal of nuclear medicine and molecular imaging 44 (3) (2016)